Can an RNA shot teach the immune system to ignore cedar pollen?
NCT ID NCT07726147
First seen Jul 24, 2026 · Last updated Jul 24, 2026
Summary
This early-stage trial tests an experimental RNA immunotherapy called ITI-9001 in adults with Japanese cedar pollen allergy. The treatment aims to retrain the immune system to reduce allergic reactions. Researchers are primarily checking safety and how well people tolerate the shot, while also looking for signs of a helpful immune response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an experimental RNA immunotherapy called ITI-9001
- What this could lead to
- If successful, this could point toward a new type of allergy treatment that trains the immune system to tolerate pollen with fewer shots than traditional immunotherapy.
- What could go wrong
- This is a very early Phase 1 trial with only 45 people, so safety and immune effects are still unknown. The treatment may cause side effects or fail to reduce allergy symptoms.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALLERGEN IMMUNOTHERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Medical Corporation Shinanokai SHINANOZAKA Clinic
RECRUITINGTokyo, Shinjuku-ku, Japan